Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.
One of the lessons from Chernobyl's legacy on health impact beyond 20 years is not only how to detect and treat the patients with radiation-associated thyroid cancers but how to follow up those who received radioactive iodine treatment repetitively after surgery in order to monitor any recurrence/worsening and also how to predict the risk of secondary primary cancers for their lifetime period. To evaluate the possibility of second primary tumors after radioactive iodine treatment, we reviewed the reports on risks from both external and internal radiation exposure, especially at high doses during childhood through an internet service of the National Library of Medicine and the National Institutes of Health, PubMed by the end of June, 2007, together with our own experience of Chernobyl childhood thyroid cancers. Children who were internally exposed after Chernobyl accident have a long-term risk of well differentiated thyroid cancers. Once they have disease, ironically radioactive iodine ablation is one of the useful therapies after surgical treatment. Elevated risks of solid cancers and leukemia have been found in radioiodine-treated patients, however, so far precious few reports from Chernobyl thyroid cancer patient were published. To reduce the adverse effects of radioactive iodine therapy on non-target tissues, recombinant human TSH has been applied and proved effective. Period of latency of second primary cancers may be very long. Therefore patients treated with high activities of radioactive iodine, especially children cases, should be carefully followed up during their whole lifespan.
Kumagai
Atsushi
A
Department of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Reiners
Christoph
C
Drozd
Valentina
V
Yamashita
Shunichi
S
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000517:prevention & control / Q000532:radiotherapy*; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000517:prevention & control; D018570:Risk Assessment; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D013972:Thyrotropin / Q000494:pharmacology; D013974:Thyroxine / Q000494:pharmacology
D007457:Iodine Radioisotopes; D013972:Thyrotropin; D013974:Thyroxine